Evaluation of a New Therapeutic Strategy in Early and Active Relapsing-Remitting Multiple Sclerosis

PHASE2TerminatedINTERVENTIONAL
Enrollment

124

Participants

Timeline

Start Date

July 31, 1999

Study Completion Date

June 30, 2006

Conditions
Relapsing-Remitting Multiple Sclerosis
Interventions
DRUG

Mitoxantrone

Trial Locations (23)

10126

Clinica Neurologica Università di Torino, Torino

13385

Chu Timone, Marseille

14033

Hôpital Cote de Nacre, Caen

16132

Neuroriabilitazione dell'Università, Genova

20132

Fondazionz SAN Raffaele del monte tabor, Milan

21013

Hospedal Civile, Gallarate

21033

Hôpital Général, Dijon

31059

CHU Purpan, Toulouse

34295

Centre Guy de Chauliac, Montpellier

50134

Dipartimento di Scienze Neurologiche e Psichiatriche, Florence

54035

CHU Hôpital Central, Nancy

59462

Institut Catholique de Lille, Lomme

63003

Hôpital Gabriel Montpied, Clermont-Ferrand

67000

CHU Strasbourg, Strasbourg

69394

Pierre Weitheimer Hospital, Lyon

70122

Psichiatriche dell'Università di Bari, Policlinico, Bari

75013

CHU Pitié-Salpétrière, Paris

75014

Hôpital Saint-Anne, Paris

75019

Centre Fondation Rotschild, Paris

87042

CHU Limoges, Limoges

94000

CHU Henri Mondor, Créteil

759170

Tenon Hospital, Paris

06000

CHU, Nice

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

Bayer

INDUSTRY

collaborator

Wyeth is now a wholly owned subsidiary of Pfizer

INDUSTRY

collaborator

Farmades, Italy

UNKNOWN

lead

Rennes University Hospital

OTHER